Merck Sharp & Dohme Corp. v. Albrecht
The Court ruled that judges, not juries, must decide whether federal drug regulators would have rejected a proposed warning label — a question that determines whether a state lawsuit against a drug company can proceed at all.
The decision also clarified an earlier ruling, explaining that a drug maker can only escape liability by showing it fully told the FDA about the risk and that the FDA specifically refused to allow a warning about it. The case, involving thousands of people who took the osteoporosis drug Fosamax, was sent back to the lower court to apply this clarified standard.
How it got here: A federal trial court granted Merck summary judgment on pre-emption grounds; the Third Circuit vacated and remanded; Merck asked the Supreme Court to resolve confusion over the standard.
The Case in Depth
What happened
Merck makes Fosamax, a drug that treats osteoporosis but that some evidence links to rare, severe thigh-bone fractures. More than 500 patients who took Fosamax and suffered these fractures between 1999 and 2010 sued Merck, arguing state law required it to warn them of the risk. Merck said federal drug regulators would have rejected any such warning before 2011, when the FDA finally required one.
The question before the Court
When a drug company says federal drug regulators would have rejected a safety warning, who decides that — a judge or a jury?
Why it matters
Thousands of people suing drug manufacturers over inadequate warnings will now have that key legal question decided by judges instead of juries, which tends to favor more predictable, uniform outcomes. Drug companies get a clearer (and fairly demanding) test for when federal approval shields them from state lawsuits, shaping how these cases are litigated nationwide.
What changes now
The case returns to the Third Circuit, which must now apply the clarified standard to decide, as a matter of law, whether Merck can show the FDA would have specifically rejected a fully-justified warning about atypical femoral fractures before 2010. This is a final decision on the legal standard and on the judge-versus-jury question, but the ultimate outcome for the Fosamax plaintiffs remains undecided.
What this does not decide
The Court did not decide whether Merck actually violated state law by failing to warn patients, or whether Merck's pre-emption defense will ultimately succeed under the clarified standard. It assumed, without deciding, that Merck had a state-law duty to warn, leaving the merits for the lower court on remand.
Concurrences and dissents
Concurrence — Justice Thomas
Justice Thomas joined the majority but wrote separately to stress that he remains skeptical of the 'physical impossibility' test generally, preferring a 'logical contradiction' approach to pre-emption. He argued that even under the Court's existing precedents, Merck's defense fails because it pointed to no formal federal law or agency action, carrying the force of law, that actually barred it from adding the warning.
Concurrence — Justice Alito
Justice Alito agreed only with the narrow holding that this is a legal question for judges, not juries, but declined to join the majority opinion. He argued the Court gave a one-sided account of the facts and downplayed a 2007 statute requiring the FDA to order label changes on its own, which he said should factor into the pre-emption analysis on remand.
How the Court got there
The legal reasoning, step by step
- The Court reviewed its 2009 decision in Wyeth v. Levine, which held that a state-law failure-to-warn claim is blocked by federal law only when there is 'clear evidence' the FDA would not have approved the warning, reflecting Congress's general reluctance to override state consumer-protection suits against drug makers.
- The Court explained that 'clear evidence' is not a special standard of proof like 'preponderance of the evidence' or 'clear and convincing evidence.' Instead, it means the manufacturer must show it fully told the FDA about the reasons for the warning and that the FDA specifically responded that it would not allow the label to be changed.
- The Court reasoned that only formal actions taken under the FDA's actual legal authority — not informal agency musings or predictions about what regulators might do — can trigger this kind of impossibility pre-emption, because the Constitution's Supremacy Clause only gives special force to actual 'Laws of the United States.'
- Turning to who decides this question, the Court concluded it is a legal question for judges rather than a factual question for juries, because it requires interpreting what an administrative agency's actions and records mean within a complex regulatory scheme — work courts are better equipped to do than lay juries.
- The Court acknowledged that judges may sometimes need to resolve disputed underlying facts, such as what information a manufacturer actually gave the FDA, but held that these factual disputes are folded into the judge's legal analysis rather than being handed to a jury.
Doctrinal impact
Cases affected by this decision
Reaffirms Wyeth v. Levine (555 U. S. 555)
The Court kept Wyeth's 'clear evidence' pre-emption rule but clarified exactly what evidence satisfies it.